|
|
News Breaks | | | | August 14, 2012 | | 16:24 EDT |  | ALNY, AZN | Alnylam, AstraZeneca form strategic alliance for microRNA
Regulus Therapeutics announced that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are currently in pre-clinical development. These targets are focused on cardiovascular and metabolic diseases and oncology. Under the terms of the agreement, AstraZeneca will make a $28M payment which includes an equity investment and an upfront payment to Regulus. Regulus and AstraZeneca will collaborate on three microRNA targets, which include Regulus' lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis. Regulus will lead preclinical development and, if successful, could receive pre-clinical milestone payments. AstraZeneca will lead and fund the clinical development and commercialization of these programs. | |
|
News For ALNY;AZN From The Last 14 Days Check below for free stories on ALNY;AZN the last two weeks. |
|
|
| May 22, 2013 | | 11:53 EDT |  | ALNY | High option volume stocks: UAN MYL ALNY SKS XIDE
 Subscribe for More Information | | | 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information | | | 07:28 EDT |  | ALNY | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link | | | May 21, 2013 | | 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). | | | May 17, 2013 | | 10:36 EDT | | AZN | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information | | | 08:41 EDT | | AZN | Impax commenced shipment of authorized generic Zomig
Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. | | | 08:04 EDT | | ALNY | Alnylam announces proof-of-concept data from RNAi program
Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT | | ALNY | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 14, 2013 | | 08:43 EDT |  | ALNY | Alnylam has multiple upcoming positive catalysts, says JMP Securities
JMP Securities believes that Alnylam will have multiple positive data catalysts over the next two months. The firm thinks that upcoming data and presentations will enhance the company's positioning and perception of its pipeline, and it keeps an Outperform rating on the shares. | | | 07:24 EDT | | AZN | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | | May 13, 2013 | | 16:53 EDT |  | AZN | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link | | | 15:55 EDT | | AZN | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information | | | May 10, 2013 | | 11:48 EDT | | AZN | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | May 9, 2013 | | 10:17 EDT | | AZN | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information | |
|
|
|
|
|
|
